

Ultrasound Imaging and Guidance for Tamoxifen-Associated Achilles Tendinopathy

© Berkay Yalçınkaya, № Ahmet Furkan Çolak, № Murat Kara, № Levent Özçakar Department of Physical and Rehabilitation Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey

Cite this article as: Yalçınkaya B, Çolak AF, Kara M, Özçakar L. Ultrasound imaging and guidance for tamoxifen-associated achilles tendinopathy. Eur J Breast Health.

Dear Editor,

A 62-year-old woman with a body mass index of 22 kg/m² was seen for intermittent right ankle pain persisting for the last two years. She identified the pain mainly over the Achilles tendon and this was worse during walking. Her medical history was notable for breast cancer, treated with modified radical mastectomy five years earlier. She had been receiving tamoxifen since then, but it was stopped six months prior to presentation due to severe ankle pain. Cessation of tamoxifen led to moderate symptom relief. Her medical history was otherwise unremarkable. On physical examination, the right Achilles tendon was painful to palpation. Ultrasound examination revealed significant tendinosis (particularly at the myotendinous junction) and partial rupture in the right Achilles tendon (Figure 1). Ultrasound-guided platelet-rich plasma injection was performed in the ruptured area as well as the myotendinous junction (Video 1). Three weeks after the intervention, her complaints were reported to have improved by 50% and the tendon thickness at the level of the lateral malleolus (1) decreased from 6.0 mm to 4.6 mm. Her bone mineral density measurement revealed osteopenic values (T-scores ranged from -1.3 to -2.2) in both lumbar vertebrae and femur. Following a follow-up visit, cold therapy, and exercises (range of motion, stretching, and strengthening of ankle muscles) were started. During this conservative treatment, her symptoms gradually decreased further. The patient is still under uneventful follow-up two months later.

Discussion

Drug-induced tendinopathy can be caused by a variety of medications, including statins, fluoroquinolones, steroids, and aromatase inhibitors. Increased metalloproteinase and collagenase activity and decreased collagen synthesis may be contributory in the pathogenesis. Tendinopathy can ensue and resolve in a widely variable period (two weeks - four years) after the drug initiation/discontinuation (2).

Tamoxifen is a selective estrogen receptor modulator (SERM) which is commonly used for the treatment of breast cancer - particularly in premenopausal women with estrogen receptor positive breast cancer (3). It has both estrogenic and anti-estrogenic effects on various tissues through regulation of the expression level and/or activity of the estrogen receptors. Although its effects on tendons are less well-documented, estrogen is known to enhance collagen synthesis in tendons and reduce tendon stiffness (4). Regarding SERMs, tamoxifen may adversely affect tendons/ligaments, potentially leading to rupture, through mechanisms such as increased metalloproteinase 13 activity, decreased tensile strength, and reduced maximum load at failure (5-7).

Since the presented patient did not have potential risk factors for Achilles tendinopathy/rupture, as she was non-obese, sedentary, had no trauma and got better after drug discontinuation, tamoxifen appears to be the most likely reason for Achilles tendon injury. Needless to say, further studies are needed to explore the possible causal relationship




Figure 1. Axial (A) and longitudinal (B) ultrasound images demonstrate Achilles tendon (stars), ruptured area (arrows) and a small ganglion cyst (asterisk). Comparative longitudinal ultrasound images (C, D) show the swollen Achilles tendon on the symptomatic side (D)

Received: 12.12.2024 Accepted: 15.01.2025 Epub: 14.02.2025

Eur J Breast Health

between tamoxifen use and tendinopathy whereby ultrasound imaging and guidance would be contributory.



Video 1. Real time ultrasound guidance during plateletrich plasma injection for ruptured area (arrow) of the Achilles tendon (star). The needle (arrowhead) is inserted using the direct in-plane technique. Asterisk, injection material; curved arrow, small anechoic ganglion cyst.

Footnotes

Authorship Contributions

Concept: M.K., L.Ö.; Design: M.K., L.Ö.; Literature Search: B.Y., A.F.Ç.; Writing: B.Y., A.F.Ç., M.K., L.Ö.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declare that they received no financial support for this study.

References

Özçakar L, Kara M, Chang KV, Bayram Çarli A, Hung CY, Tok F, et al. EURO-MUSCULUS/USPRM. basic scanning protocols for ankle and foot. Eur J Phys Rehabil Med. 2015; 51: 647-653. (PMID: 26351106) [Crossref]

- Cohen PR. Cephalexin-associated achilles tendonitis: case report and review of drug-induced tendinopathy. Cureus. 2018; 10: e3783. (PMID: 30915263) [Crossref]
- Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, et al. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell Death Dis. 2024; 15: 418. (PMID: 38879508) [Crossref]
- Leblanc DR, Schneider M, Angele P, Vollmer G, Docheva D. The effect of estrogen on tendon and ligament metabolism and function. J Steroid Biochem Mol Biol. 2017; 172: 106-116. (PMID: 28629994) [Crossref]
- Irie T, Takahata M, Majima T, Abe Y, Komatsu M, Iwasaki N, et al. 5. Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast. Connect Tissue Res. 2010; 51: 179-187. (PMID: 20073985) [Crossref]
- Shahryarinejad A, Gardner TR, Cline JM, Levine WN, Bunting HA, Brodman MD, et al. Effect of hormone replacement and selective estrogen receptor modulators (SERMs) on the biomechanics and biochemistry of pelvic support ligaments in the cynomolgus monkey (Macaca fascicularis). Am J Obstet Gynecol. 2010; 202: 485.e1-e9. (PMID: 20452495) [Crossref]
- Best KT, Studentsova V, Ackerman JE, Nichols AEC, Myers M, Cobb J, et al. Effects of tamoxifen on tendon homeostasis and healing: considerations for the use of tamoxifen-inducible mouse models. J Orthop Res. 2021; 39: 1572-1580. (PMID: 32485026) [Crossref]